VAL-083 is effective in patients with newly-diagnosed MGMT-unmethylated glioblastoma: report of phase II study

Abstract Purpose Unmethylated MGMT is a validated biomarker for temozolomide (TMZ) resistance and poor prognosis in glioblastoma. VAL-083 (dianhydrogalactitol; DAG) is a DNA-targeting agent that forms interstrand crosslinks at O6/N7-guanine, inducing double-strand breaks and cell death independently...

Descripció completa

Dades bibliogràfiques

Autors principals:	Chengcheng Guo, Qunying Yang, Meiling Deng, Xiaoling Qiu, Shaoxiong Wu, Xiaojing Du, Ke Sai, Ziyu Dai, Zhenghe Chen, Ji Zhang, Fuhua Lin, Chao Ke, Shaoyan Xi, Wanming Hu, Zhihuan Zhou, Jiawei Li, Xi Cao, Yixiang Liao, Yanchun Lv, Dennis Brown, John Langlands, Gregory Johnson, Jeffrey Bacha, Claire Kwan, Sarath Kanekal, Richard Schwartz, Zhongping Chen
Format:	Artigo
Idioma:	Inglês
Publicat:	Springer 2025-12-01
Col·lecció:	Discover Oncology
Matèries:	VAL-083 Glioblastoma Radiation Newly-diagnose MGMT-unmethylated
Accés en línia:	https://doi.org/10.1007/s12672-025-04235-y
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!